This is an old revision of the document!
Over the years, physicians have voiced various concerns about the Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis., concerns ranging from the safety of higher doses of olmesartan (Benicar)Medication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. to concerns about long-term antibiotic use. The Autoimmunity Research FoundationNon-profit foundation dedicated to exploring a pathogenesis and therapy for chronic disease. has assembled articles, well-grounded in scientific research, which address these concerns. Physicians who choose to use and administer the MP do so on the basis of the available evidence.
<html></p><div id=“marginleft30”></html>
For some physicians, the above evidence is not sufficiently compelling to warrant automatically starting a patient on the MP without further consideration. Here are some other factors which may play a role in the clinical judgment:
Finally, a physician may want to try their patient on a therapeutic probeA brief trial of the Marshall Protocol to see if it will generate an immunopathological response. The "gold standard" for testing whether a patient is a good candidate for the MP.. While the randomized controlled trial or RCT is widely praised for its validity in identifying the efficacy of a therapy, according to a well-regarded evidence-based medicine textbook produced by JAMA, “clinicians cannot always rely on the results of randomized controlled trials…. In such cases, clinicians can conduct RCTs in individual patients (n-of-1 RCTs).” According to the 2009 edition, in an N-of-1 RCT the patient begins treatment and the subsequent clinical course determines whether treatment is continued.
<html></p></div></html>
DJ posted :- During the summer of 2013 I looked at 2,000 records of people using the Marshall Protocol.
Resulting in significant information pertaining to 864 patients who maintained the Marshall Protocol over a sufficient number of years and continued to report to the study site.
Patients on the Marshall Protocol (MP) take olmesartan (Benicar)–a drug whose actions are fully known–every four to six hours. A substantial body of research supports the use of olmesartan as a part of a curative therapy for chronic disease.
Patients on the MP abstain from consumption of vitamin D. Although the secosteroid may currently enjoy a positive reputation in the media, molecular research shows that taking vitamin D exacerbates inflammatory disease.
Research with long-term followup
Thumbs Down on Calcium and Vitamin D to Prevent Hip Fracture
Evaluation of the Effect of Radiofrequency Radiation Emitted From Wi-Fi Router and Mobile Phone Simulator on the Antibacterial Susceptibility of Pathogenic Bacteria Listeria monocytogenes and Escherichia coli.
Altogether, the findings of this study showed that exposure to Wi-Fi and RF simulator radiation can significantly alter the inhibition zone diameters and growth rate for L monocytogenes and E coli. These findings may have implications for the management of serious infectious diseases. 3)
Previous studies have shown that exposure of microorganisms to RF-EMFs can be associated with a wide spectrum of changes ranged from the modified bacterial growth to the alterations of the pattern of antibiotic resistance.
Our laboratory at the nonionizing department of the Ionizing and Non-ionizing Radiation Protection Research Center has performed experiments on the health effects of exposure to animal models and humans to different sources of electromagnetic fields such as cellular phones, mobile base stations, mobile phone jammers, laptop computers, radars, dentistry cavitrons, magnetic resonance imaging, and Helmholtz coils.
— Sallie Q 08.19.2017 removed another non-functioning link to JAMA and edited link to fda policy on off-label Px
— Sallie Q 06.04.2017 removing non-functional link Read more → adding ref. EMF can affect bacteria, increasing resistance to ABx